Drug safety evaluation profile of stavudine plus lamivudine for HIV-1/AIDS infection

Abstract

Introduction: The lamivudine (3TC) + stavudine (d4T) combination is still widely used as part of first-line therapy for HIV-1-infected patients in low-resource countries. This review is intended to assess the benefits and risks in terms of safety of d4T + 3TC-based combination antiretroviral therapy (ART) for the treatment of HIV-1 infection.

Areas covered: The most relevant papers related to the safety of d4T + 3TC-based ART were selected and summarized.

Expert opinion: In industrialized countries, the 3TC + d4T combination is not recommended for initial therapy because of long-term metabolic toxicities associated with d4T. In developing countries, it may have a role in the treatment of HIV-infected patients if there is no other chance for starting antiretroviral therapy.

Keywords::

• AIDS
• antiretroviral treatment
• HIV-1 infection
• lamivudine
• safety
• stavudine
• toxicity

Acknowledgements

The figures have been modified from prior presentations.

Notes

This box summarizes key points contained in the article.